Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists

References

• Aparasu RR, Bhatara V. Antipsychotic prescribing trends among youths, 1997–2002. Psychiatric Services 2005; 56: 904
   PubMed Web of Science ®Google Scholar
• Aparasu RR, Bhatara V. Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003–2004. Current Medical Research and Opinion 2007; 23: 48–55
   Web of Science ®Google Scholar
• Cooper WO, Arbogast PG, Ding H, Hickson GB, Fuchs C, Ray WA. Trends in prescribing of antipsychotic medications for US children. Ambulatory Pediatrics 2006; 6: 79–83
   PubMedGoogle Scholar
• Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA. New users of antipsychotic medications among children enrolled in TennCare. Archives of Pediatrics and Adolescent Medicine 2004; 158: 753–759
   PubMed Web of Science ®Google Scholar
• Patel NC, Sanchez RJ, Johnsrud MT, Crismon ML. Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996 to 2000. Journal of Child and Adolescent Psychopharmacology 2006; 12: 221–229
   Google Scholar
• Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry 2006; 63: 679–685
   PubMed Web of Science ®Google Scholar
• Patel NC, Crismon ML, Hoagwood K, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 2005; 44: 548–556
   PubMed Web of Science ®Google Scholar
• Efron D, Hiscock H, Sewell JR, et al. Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists. Pediatrics 2003; 111: 372–375
   PubMed Web of Science ®Google Scholar
• Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. Journal of Child and Adolescent Psychopharmacology 2004; 14: 372–394
   PubMed Web of Science ®Google Scholar
• Findling RL, McNamara NK. Atypical antipsychotics in the treatment of children and adolescents: Clinical applications. Journal of Clinical Psychiatry 2004; 65: 30–44
   PubMed Web of Science ®Google Scholar
• Jensen PS, Buitelaar J, Pandina GJ, Binder C, Haas M. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. European Child and Adolescent Psychiatry 2007; 16: 104–120
   PubMed Web of Science ®Google Scholar
• Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. Journal of Clinical Psychiatry 2005; 66(Suppl. 7)29–40
   PubMedGoogle Scholar
• McConville BJ, Sorter MT, McConville BJ, Sorter MT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. Journal of Clinical Psychiatry 2004; 65(Suppl. 6)20–29
   PubMedGoogle Scholar
• Patel NC, Crismon M, Hoagwood K, Jensen PS. Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. Journal of Child and Adolescent Psychopharmacology 2005; 15: 270–284
   PubMed Web of Science ®Google Scholar
• Connor DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. Journal of Clinical Psychiatry 2001; 62: 967–974
   PubMed Web of Science ®Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry 2004; 161: 414–425
   PubMed Web of Science ®Google Scholar
• Correll CU, Kane JM. One-year tardive dyskinesia rates in children and adolescents treated with second-generation antipsychotics: A systematic review. Journal of Child and Adolescent Psychopharmacology 2007; 17: 647–655
   PubMed Web of Science ®Google Scholar
• Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 2006; 45: 771–791
   PubMed Web of Science ®Google Scholar
• Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child and Adolescent Psychiatric Clinics of North America 2006; 15: 177–206
   PubMed Web of Science ®Google Scholar
• Kapetanovic S, Simpson GM. Review of antipsychotics in children and adolescents. Expert Opinion on Pharmacotherapy 2006; 7: 1871–1885
   PubMed Web of Science ®Google Scholar
• Toren P, Ratner S, Laor N, Weizman A. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Safety 2004; 27: 1135–1156
   PubMed Web of Science ®Google Scholar
• Fedorowicz VJ, Fombonne E. Metabolic side effects of atypical antipsychotics in children: a literature review. Journal of Psychopharmacology 2005; 19: 533–550
   PubMed Web of Science ®Google Scholar
• Bryden KE, Carrey NJ, Kutcher SP. Update and recommendations for the use of antipsychotics in early-onset psychoses. Journal of Child and Adolescent Psychopharmacology 2001; 11: 113–130
   PubMed Web of Science ®Google Scholar
• Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. Journal of the American Academy of Child and Adolescent Psychiatry. 2007; 46: 687–700
   PubMed Web of Science ®Google Scholar
• Gracious BL, Findling RL. Antipsychotic medications for children and adolescents. Pediatric Annals 2001; 30: 138–145
   PubMed Web of Science ®Google Scholar
• Stigler KA, Potenza MN, Posey DJ, McDougle CJ. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatric Drugs 2004; 6: 33–44
   PubMedGoogle Scholar
• Masi G, Mucci M, Pari C. Children with schizophrenia: clinical picture and pharmacological treatment. CNS Drugs 2006; 20: 841–866
   PubMed Web of Science ®Google Scholar
• Stigler KA, Potenza MN, McDougle CJ. Tolerability profile of atypical antipsychotics in children and adolescents. Paediatric Drugs 2001; 3: 927–942
   PubMedGoogle Scholar
• Correll CU. Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. Journal of the American Academy of Child and Adolescent Psychiatry 2008; 47: 9–20
   PubMed Web of Science ®Google Scholar
• Safer DJ. A comparison of risperidone-induced weight gain across the age span. Journal of Clinical Psychopharmacology 2004; 24: 429–436
   PubMed Web of Science ®Google Scholar
• Fleischhaker C, Heiser P, Hennighausen K, et al. Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. Journal of Neural Transmission 2007; 114: 273–280
   PubMed Web of Science ®Google Scholar
• Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. Journal of the American Academy of Child and Adolescent Psychiatry 2002; 41: 337–343
   PubMed Web of Science ®Google Scholar
• Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Safety 2006; 29: 303–319
   PubMed Web of Science ®Google Scholar
• Ebbeling CB, Pawlak DB, Ludwig DS. Childhood obesity: public-health crisis, common sense cure. The Lancet 2002; 360: 473–482
   PubMed Web of Science ®Google Scholar
• Hong Y, Jin X, Mo J, et al. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality – results of prospective analysis for the Atherosclerosis Risk in Communities study. Journal of Internal Medicine 2007; 262: 113–122
   PubMed Web of Science ®Google Scholar
• Martin A, L'Ecuyer S. Triglyceride, cholesterol and weight changes among risperidone-treated youths: a retrospective study. European Child and Adolescent Psychiatry 2002; 11: 129–133
   PubMed Web of Science ®Google Scholar
• Patel NC, Hariparsad M, Matias-Akthar M, et al. Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology 2007; 17: 303–311
   PubMed Web of Science ®Google Scholar
• Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. The American Journal of Psychiatry 2007; 164: 1547–1556
   PubMed Web of Science ®Google Scholar
• Guo JJ, Keck PE, Jr, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. Journal of Clinical Psychiatry 2006; 67: 1055–1061
   PubMed Web of Science ®Google Scholar
• Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003; 23: 735–744
   PubMed Web of Science ®Google Scholar
• Guo JJ, Keck PE, Jr, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study. Pharmacotherapy 2007; 27: 27–35
   PubMed Web of Science ®Google Scholar
• Koller EA, Cross JT, Schneider B. Risperidone-associated diabetes mellitus in children. Pediatrics 2004; 113: 421–422
   PubMed Web of Science ®Google Scholar
• Bottai T, Quintin P, Perrin E. Antipsychotics and the risk of diabetes: a general data review. European Psychiatry 2005; 20: S349–S357
   PubMedGoogle Scholar
• Harrison-Woolrych M, Garcia-Quiroga J, Ashton J, Herbison P. Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Safety 2007; 30: 569–579
   PubMed Web of Science ®Google Scholar
• Laita P, Cifuentes A, Doll A, et al. Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. Journal of Child and Adolescent Psychopharmacology 2007; 17: 487–501
   PubMed Web of Science ®Google Scholar
• Pappagallo M, Silva R. The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. Journal of Child & Adolescent Psychopharmacology 2004; 14: 359–371
   PubMed Web of Science ®Google Scholar
• Saito E, Correll CU, Gallelli K, et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. Journal of Child and Adolescent Psychopharmacology 2004; 14: 350–358
   PubMed Web of Science ®Google Scholar
• Staller J. The effect of long-term antipsychotic treatment on prolactin. Journal of Child and Adolescent Psychopharmacology 2006; 16: 317–326
   PubMed Web of Science ®Google Scholar
• Anderson GM, Scahill L, McCracken JT, et al. Effects of short-and long-term risperidone treatment on prolactin levels in children with autism. Biological Psychiatry 2007; 61: 545–550
   PubMed Web of Science ®Google Scholar
• Becker AL, Epperson CN, Becker AL, Epperson CN. Female puberty: clinical implications for the use of prolactin-modulating psychotropics. Child and Adolescent Psychiatric Clinics of North America 2006; 15: 207–220
   PubMed Web of Science ®Google Scholar
• Wudarsky M, Nicolson R, Hamburger SD, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology 1999; 9: 239–245
   PubMed Web of Science ®Google Scholar
• Alfaro CL, Wudarsky M, Nicolson R, et al. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. Journal of Child and Adolescent Psychopharmacology 2002; 12: 83–91
   PubMed Web of Science ®Google Scholar
• Dunbar F, Kusumakar V, Daneman D, Schulz M. Growth and sexual maturation during long-term treatment with risperidone. American Journal of Psychiatry 2004; 161: 918–920
   PubMed Web of Science ®Google Scholar
• Blair J, Scahill L, State M, Martin A. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study [see comment]. Journal of the American Academy of Child and Adolescent Psychiatry 2005; 44: 73–79
   PubMed Web of Science ®Google Scholar
• Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. Journal of Clinical Psychiatry 2007; 68(Suppl. 6)10–13
   PubMedGoogle Scholar
• Gonzalez-Heydrich J, Raches D, Wilens TE, Leichtner A, Mezzacappa E. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42: 1227–1233
   PubMed Web of Science ®Google Scholar
• Pappadopulos E, Jensen PS, Schur SB, et al. Real world” atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophrenia Bulletin 2002; 28: 111–121
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Nasrallah HA, Loebel AD. The atypical antipsychotic therapy and metabolic issues national survey. Journal of Clinical Psychopharmacology 2004; 24(Suppl. 1)S1–S6
   PubMedGoogle Scholar
• Buckley PF, Miller DD, Singer B, Arena J, Stirewalt EM. Clinicians’ recognition of the metabolic adverse events of antipsychotic medications. Schizophrenia Bulletin 2005; 79: 281–288
   Google Scholar
• Ketter TA, Haupt DW. Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. Current Medical Research and Opinion 2006; 22: 2345–2353
   PubMed Web of Science ®Google Scholar
• Doey T, Handelman K, Seabrook JA, Steele M. Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Canadian Journal of Psychiatry 2007; 52: 363–368
   PubMed Web of Science ®Google Scholar
• Clark NC. Consensus development conference on antipsychotic drugs and obsesity and diabetes. Diabetes Care 2004; 27: 596–601
   PubMed Web of Science ®Google Scholar
• Vieweg WV, Sood AB, Pandurangi A, Silverman JJ. Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?. Acta Psychiatrica Scandinavica 2005; 111: 177–184
   PubMed Web of Science ®Google Scholar
• Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse effects in children and adolescents. International Review of Psychiatry (in press).
   Google Scholar
• Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation. Evaluating the risk/benefit equation and improving the standard of care. Journal of Clinical Psychopharmacology 2004; 24(Suppl. 1)S7–S14
   PubMedGoogle Scholar
• Correll CU. Balancing efficacy and safety in treatment with antipsychotics. CNS Spectrums 2007; 12(Suppl. 17)12–20
   PubMed Web of Science ®Google Scholar